Screener / SEC EDGAR /CIK 0001822479 /10-K filed Feb 24, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Health Services

Sotera Health Co SHC

Compare with peers Embed

SHC among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+5.7%110th of 155 · median +10.5%
Net margin
-4.1%15.3%
14.1%42nd of 154 · median 6.8%
Return on equity
-5.2%18.5%
23.7%23rd of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
11.0%70th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
2.91102nd of 108 · median 0.69

SHC and 9 peers, year by year

The 9 Health care companies closest to SHC in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
SHC Sotera Health Co FY2025 $1.2B+5.7%55.5%-6.7%12.8%12.9%3.53
TECH Bio-Techne FY2026 $1.2B−0.4%65.8%20.7%15.0%21.7%8.6%0.09
ACAD Acadia Pharmaceuticals Inc FY2025 $1.1B+11.9%-9.8%36.5%9.8%31.9%-
GH Guardant Health, Inc. FY2025 $982.0M+32.9%-−44.5%−42.4%−23.7%n/mn/m
PBH Prestige Consumer Healthcare Inc. FY2026 $1.1B−4.3%54.7%28.4%17.5%22.6%10.1%0.53
PGNY Progyny, Inc. FY2025 $1.3B+10.4%23.6%6.6%4.5%14.9%11.3%-
HAE Haemonetics Corp FY2026 $1.3B−2.0%59.0%11.7%7.3%19.5%12.2%1.56
CAI Caris Life Sciences, Inc. FY2025 $812.0M+97.0%-5.6%−8.4%8.2%−11.8%0.66
MDGL Madrigal Pharmaceuticals, Inc. FY2025 $958.4M+432%-−31.3%−30.1%−19.8%−47.8%0.56
CORT Corcept Therapeutics Inc FY2025 $761.4M+12.8%-5.9%13.1%18.6%15.4%-

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2019 to FY2025 · 10-K XBRL

SHCSotera Health Co
FY2019 revenue $778.3MFY2020 revenue $818.2MFY2021 revenue $931.5MFY2022 revenue $1.0BFY2023 revenue $1.0BFY2024 revenue $1.1BFY2025 revenue $1.2B FY2019 net margin −2.7%FY2020 net margin −4.7%FY2021 net margin 12.5%FY2022 net margin −23.3%FY2023 net margin 4.9%FY2024 net margin 4.0%FY2025 net margin 6.7% FY2019FY2025
Revenue$1.2B Growth+5.7% Net margin6.7%
TECHBio-Techne
FY2019 revenue $714.0MFY2020 revenue $738.7MFY2021 revenue $931.0MFY2022 revenue $1.1BFY2023 revenue $1.1BFY2024 revenue $1.2BFY2025 revenue $1.2B FY2019 net margin 13.5%FY2020 net margin 31.0%FY2021 net margin 15.1%FY2022 net margin 24.6%FY2023 net margin 25.1%FY2024 net margin 14.5%FY2025 net margin 6.0% FY2019FY2025
Revenue$1.2B Growth+5.2% Net margin6.0%
ACADAcadia Pharmaceuticals Inc
FY2019 revenue $339.1MFY2020 revenue $441.8MFY2021 revenue $484.1MFY2022 revenue $517.2MFY2023 revenue $726.4MFY2024 revenue $957.8MFY2025 revenue $1.1B FY2019 net margin −69.4%FY2020 net margin −63.7%FY2021 net margin −34.7%FY2022 net margin −41.8%FY2023 net margin −8.4%FY2024 net margin 23.6%FY2025 net margin 36.5% FY2019FY2025
Revenue$1.1B Growth+11.9% Net margin36.5%
GHGuardant Health, Inc.
FY2019 revenue $214.4MFY2020 revenue $286.7MFY2021 revenue $373.7MFY2022 revenue $449.5MFY2023 revenue $563.9MFY2024 revenue $739.0MFY2025 revenue $982.0M FY2019 net margin −35.3%FY2020 net margin −88.5%FY2021 net margin −103.0%FY2022 net margin −145.6%FY2023 net margin −85.0%FY2024 net margin −59.0%FY2025 net margin −42.4% FY2019FY2025
Revenue$982.0M Growth+32.9% Net margin−42.4%
PBHPrestige Consumer Healthcare Inc.
FY2019 revenue $975.8MFY2020 revenue $963.0MFY2021 revenue $943.4MFY2022 revenue $1.1BFY2023 revenue $1.1BFY2024 revenue $1.1BFY2025 revenue $1.1B FY2019 net margin −3.7%FY2020 net margin 14.8%FY2021 net margin 17.5%FY2022 net margin 18.9%FY2023 net margin −7.3%FY2024 net margin 18.6%FY2025 net margin 18.9% FY2019FY2025
Revenue$1.1B Growth+1.1% Net margin18.9%
PGNYProgyny, Inc.
FY2019 revenue $229.7MFY2020 revenue $344.9MFY2021 revenue $500.6MFY2022 revenue $786.9MFY2023 revenue $1.1BFY2024 revenue $1.2BFY2025 revenue $1.3B FY2019 net margin −3.7%FY2020 net margin 13.5%FY2021 net margin 13.1%FY2022 net margin 3.9%FY2023 net margin 5.7%FY2024 net margin 4.7%FY2025 net margin 4.5% FY2019FY2025
Revenue$1.3B Growth+10.4% Net margin4.5%
HAEHaemonetics Corp
FY2019 revenue $967.6MFY2020 revenue $988.5MFY2021 revenue $870.5MFY2022 revenue $993.2MFY2023 revenue $1.2BFY2024 revenue $1.3BFY2025 revenue $1.4B FY2019 net margin 5.7%FY2020 net margin 7.7%FY2021 net margin 9.1%FY2022 net margin 4.4%FY2023 net margin 9.9%FY2024 net margin 9.0%FY2025 net margin 12.3% FY2019FY2025
Revenue$1.4B Growth+4.0% Net margin12.3%
CAICaris Life Sciences, Inc.
FY2023 revenue $306.1MFY2024 revenue $412.3MFY2025 revenue $812.0M FY2023 net margin −111.5%FY2024 net margin −68.4%FY2025 net margin −8.4% FY2019FY2025
Revenue$812.0M Growth+97.0% Net margin−8.4%
MDGLMadrigal Pharmaceuticals, Inc.
FY2024 revenue $180.1MFY2025 revenue $958.4M FY2024 net margin −258.6%FY2025 net margin −30.1% FY2019FY2025
Revenue$958.4M Growth+432% Net margin−30.1%
CORTCorcept Therapeutics Inc
FY2019 revenue $306.5MFY2020 revenue $353.9MFY2021 revenue $366.0MFY2022 revenue $401.9MFY2023 revenue $482.4MFY2024 revenue $675.0MFY2025 revenue $761.4M FY2019 net margin 30.7%FY2020 net margin 30.0%FY2021 net margin 30.7%FY2022 net margin 25.2%FY2023 net margin 22.0%FY2024 net margin 20.9%FY2025 net margin 13.1% FY2019FY2025
Revenue$761.4M Growth+12.8% Net margin13.1%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2019 to FY2025

Revenue as reported in the 10-K.

$0 $1.4B FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TECH: $714.0M, $738.7M, $931.0M, $1.1B, $1.1B, $1.2B, $1.2B TECH ACAD: $339.1M, $441.8M, $484.1M, $517.2M, $726.4M, $957.8M, $1.1B ACAD GH: $214.4M, $286.7M, $373.7M, $449.5M, $563.9M, $739.0M, $982.0M GH PBH: $975.8M, $963.0M, $943.4M, $1.1B, $1.1B, $1.1B, $1.1B PBH PGNY: $229.7M, $344.9M, $500.6M, $786.9M, $1.1B, $1.2B, $1.3B PGNY HAE: $967.6M, $988.5M, $870.5M, $993.2M, $1.2B, $1.3B, $1.4B HAE CAI: -, -, -, -, $306.1M, $412.3M, $812.0M CAI MDGL: $0, $0, $0, $0, $0, $180.1M, $958.4M MDGL CORT: $306.5M, $353.9M, $366.0M, $401.9M, $482.4M, $675.0M, $761.4M CORT SHC: $778.3M, $818.2M, $931.5M, $1.0B, $1.0B, $1.1B, $1.2B SHC
SHC is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $1.4B. A gap is a year with no number. A ring marks where a line starts: CAI has no earlier 10-K here.

Sales growth, FY2019 to FY2025

Revenue against the fiscal year before.

−11.9% +432% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TECH: +11.0%, +3.5%, +26.0%, +18.7%, +2.8%, +2.0%, +5.2% TECH ACAD: +51.5%, +30.3%, +9.6%, +6.8%, +40.4%, +31.8%, +11.9% ACAD GH: +137%, +33.8%, +30.3%, +20.3%, +25.5%, +31.0%, +32.9% GH PBH: −6.3%, −1.3%, −2.0%, +15.2%, +3.8%, −0.2%, +1.1% PBH PGNY: +118%, +50.1%, +45.2%, +57.2%, +38.3%, +7.2%, +10.4% PGNY HAE: +7.0%, +2.2%, −11.9%, +14.1%, +17.7%, +12.0%, +4.0% HAE CAI: -, -, -, -, -, +34.7%, +97.0% CAI MDGL: -, -, -, -, -, -, +432% MDGL CORT: +22.0%, +15.5%, +3.4%, +9.8%, +20.0%, +39.9%, +12.8% CORT SHC: -, +5.1%, +13.9%, +7.8%, +4.5%, +4.9%, +5.7% SHC
SHC is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −11.9% to +432%. A gap is a year with no number. A ring marks where a line starts: SHC, CAI, MDGL have no earlier 10-K here.

Gross margin, FY2019 to FY2025

Gross profit / revenue.

19.8% 98.0% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TECH: 66.3%, 65.4%, 68.0%, 68.4%, 67.7%, 66.4%, 64.8% TECH ACAD: 96.7%, 97.7%, 97.8%, 98.0%, 94.3%, -, - ACAD PBH: 56.9%, 57.3%, 58.0%, 57.1%, 55.4%, 55.5%, 55.8% PBH PGNY: 19.8%, 20.3%, 22.4%, 21.3%, 21.9%, 21.7%, 23.6% PGNY HAE: 43.2%, 49.0%, 45.7%, 50.9%, 52.6%, 52.8%, 55.0% HAE SHC: 50.8%, 54.2%, 55.7%, 55.5%, 55.0%, 54.7%, 55.5% SHC
SHC is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 19.8% to 98.0%. A gap is a year with no number.
CompanyFY2019FY2020FY2021FY2022FY2023FY2024FY2025
SHC Dec 50.8%54.2%55.7%55.5%55.0%54.7%55.5%
TECH Jun 66.3%65.4%68.0%68.4%67.7%66.4%64.8%
ACAD Dec 96.7%97.7%97.8%98.0%94.3%--
GH Dec -------
PBH Mar 56.9%57.3%58.0%57.1%55.4%55.5%55.8%
PGNY Dec 19.8%20.3%22.4%21.3%21.9%21.7%23.6%
HAE Mar 43.2%49.0%45.7%50.9%52.6%52.8%55.0%
CAI Dec -------
MDGL Dec -------
CORT Dec -------
Peer median56.9%57.3%58.0%57.1%55.4%54.2%55.4%

Operating margin, FY2019 to FY2025

Operating income / revenue.

−276.4% 36.4% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TECH: 20.5%, 21.3%, 25.5%, 26.8%, 26.3%, 17.8%, 8.4% TECH ACAD: −72.7%, −64.9%, −35.2%, −43.2%, −10.1%, 24.1%, 9.8% ACAD GH: −38.4%, −88.9%, −110.0%, −121.1%, −100.1%, −60.0%, −44.5% GH PBH: 6.9%, 30.2%, 31.5%, 30.4%, −2.0%, 30.4%, 29.6% PBH PGNY: 4.2%, 2.4%, 6.5%, 3.0%, 5.7%, 5.8%, 6.6% PGNY HAE: 8.6%, 10.5%, 10.3%, 8.1%, 13.4%, 12.6%, 16.3% HAE CAI: -, -, -, -, −104.4%, −62.4%, 5.6% CAI MDGL: -, -, -, -, -, −276.4%, −31.3% MDGL CORT: 36.4%, 36.2%, 34.0%, 28.0%, 22.2%, 20.3%, 5.9% CORT SHC: 23.6%, 25.2%, 27.6%, 24.7%, 26.4%, 27.0%, - SHC
SHC is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −276.4% to 36.4%. A gap is a year with no number. A ring marks where a line starts: CAI, MDGL have no earlier 10-K here.

Net margin, FY2019 to FY2025

Net income / revenue.

−258.6% 36.5% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TECH: 13.5%, 31.0%, 15.1%, 24.6%, 25.1%, 14.5%, 6.0% TECH ACAD: −69.4%, −63.7%, −34.7%, −41.8%, −8.4%, 23.6%, 36.5% ACAD GH: −35.3%, −88.5%, −103.0%, −145.6%, −85.0%, −59.0%, −42.4% GH PBH: −3.7%, 14.8%, 17.5%, 18.9%, −7.3%, 18.6%, 18.9% PBH PGNY: −3.7%, 13.5%, 13.1%, 3.9%, 5.7%, 4.7%, 4.5% PGNY HAE: 5.7%, 7.7%, 9.1%, 4.4%, 9.9%, 9.0%, 12.3% HAE CAI: -, -, -, -, −111.5%, −68.4%, −8.4% CAI MDGL: -, -, -, -, -, −258.6%, −30.1% MDGL CORT: 30.7%, 30.0%, 30.7%, 25.2%, 22.0%, 20.9%, 13.1% CORT SHC: −2.7%, −4.7%, 12.5%, −23.3%, 4.9%, 4.0%, 6.7% SHC
SHC is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −258.6% to 36.5%. A gap is a year with no number. A ring marks where a line starts: CAI, MDGL have no earlier 10-K here.

Free cash flow, FY2019 to FY2025

Cash from operations minus capital spending.

−$457.0M $307.9M FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TECH: $156.2M, $153.5M, $307.9M, $280.4M, $216.1M, $236.1M, $256.6M TECH ACAD: −$152.3M, −$143.8M, −$126.8M, −$114.0M, $16.7M, $157.2M, $105.1M ACAD GH: −$65.9M, −$140.1M, −$284.1M, −$386.9M, −$345.5M, −$274.9M, −$233.1M GH PBH: $178.8M, $202.6M, $213.4M, $250.3M, $221.9M, $239.4M, $243.3M PBH PGNY: −$4.5M, $35.2M, $23.9M, $77.2M, $185.2M, $173.7M, $191.8M PGNY HAE: $40.3M, $109.5M, $71.8M, $75.8M, $81.7M, $143.6M, $142.4M HAE CAI: -, -, -, -, −$298.4M, −$253.6M, $66.9M CAI MDGL: −$41.8M, −$157.9M, −$184.1M, −$225.1M, −$325.7M, −$457.0M, −$190.0M MDGL CORT: $135.0M, $150.7M, $167.4M, $119.9M, $126.5M, $196.1M, $141.8M CORT SHC: $91.8M, $67.1M, $179.4M, $95.6M, −$362.7M, $45.1M, $149.2M SHC
SHC is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$457.0M to $307.9M. A gap is a year with no number. A ring marks where a line starts: CAI has no earlier 10-K here.

FCF margin, FY2019 to FY2025

Free cash flow / revenue.

−253.7% 45.7% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TECH: 21.9%, 20.8%, 33.1%, 25.4%, 19.0%, 20.4%, 21.0% TECH ACAD: −44.9%, −32.5%, −26.2%, −22.0%, 2.3%, 16.4%, 9.8% ACAD GH: −30.7%, −48.9%, −76.0%, −86.1%, −61.3%, −37.2%, −23.7% GH PBH: 18.3%, 21.0%, 22.6%, 23.0%, 19.7%, 21.3%, 21.4% PBH PGNY: −2.0%, 10.2%, 4.8%, 9.8%, 17.0%, 14.9%, 14.9% PGNY HAE: 4.2%, 11.1%, 8.2%, 7.6%, 7.0%, 11.0%, 10.5% HAE CAI: -, -, -, -, −97.5%, −61.5%, 8.2% CAI MDGL: -, -, -, -, -, −253.7%, −19.8% MDGL CORT: 44.1%, 42.6%, 45.7%, 29.8%, 26.2%, 29.1%, 18.6% CORT SHC: 11.8%, 8.2%, 19.3%, 9.5%, −34.6%, 4.1%, 12.8% SHC
SHC is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −253.7% to 45.7%. A gap is a year with no number. A ring marks where a line starts: CAI, MDGL have no earlier 10-K here.

Return on equity, FY2019 to FY2025

Net income / shareholders' equity at the year end.

−149.6% 31.9% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TECH: 8.2%, 16.6%, 9.0%, 16.0%, 14.5%, 8.1%, 3.8% TECH ACAD: −33.7%, −44.9%, −31.0%, −53.9%, −14.2%, 30.9%, 31.9% ACAD GH: −9.5%, −19.5%, −59.7%, n/m, n/m, n/m, n/m GH PBH: −3.3%, 12.2%, 12.1%, 13.0%, −5.7%, 12.6%, 11.7% PBH PGNY: −7.5%, 27.8%, 26.1%, 8.1%, 11.2%, 12.9%, 11.3% PGNY HAE: 8.2%, 13.0%, 10.9%, 5.8%, 14.1%, 12.2%, 20.4% HAE CAI: -, -, -, -, n/m, n/m, −11.8% CAI MDGL: −20.2%, −84.3%, −123.3%, −149.6%, −92.2%, −61.8%, −47.8% MDGL CORT: 25.4%, 20.3%, 29.9%, 20.2%, 20.9%, 20.8%, 15.4% CORT SHC: n/m, −8.5%, 19.9%, −66.7%, 11.6%, 11.0%, 12.9% SHC
SHC is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −149.6% to 31.9%. A gap is a year with no number. A ring marks where a line starts: SHC, CAI have no earlier 10-K here.

Debt / equity, FY2019 to FY2025

Total debt / shareholders' equity at the year end.

0.00 5.55 FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TECH: 0.43, 0.26, 0.22, 0.15, 0.18, 0.15, 0.18 TECH PBH: 1.64, 1.48, 1.09, 0.94, 0.93, 0.68, 0.54 PBH HAE: 0.52, 0.65, 0.97, 1.03, 0.94, 0.84, 1.49 HAE CAI: -, -, -, -, -, n/m, 0.66 CAI MDGL: -, -, 0.00, 0.35, 0.28, 0.16, 0.56 MDGL SHC: -, 4.03, 2.97, 5.55, 5.02, 5.49, 3.53 SHC
SHC is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 5.55. A gap is a year with no number. A ring marks where a line starts: SHC, CAI, MDGL have no earlier 10-K here.
CompanyFY2019FY2020FY2021FY2022FY2023FY2024FY2025
SHC Dec -4.032.975.555.025.493.53
TECH Jun 0.430.260.220.150.180.150.18
ACAD Dec -------
GH Dec -----n/mn/m
PBH Mar 1.641.481.090.940.930.680.54
PGNY Dec -------
HAE Mar 0.520.650.971.030.940.841.49
CAI Dec -----n/m0.66
MDGL Dec --0.000.350.280.160.56
CORT Dec -------
Peer median0.520.650.590.640.610.420.56

EPS (diluted), FY2019 to FY2025

Diluted earnings per share, on today's share count after splits.

−$21.90 $4.29 FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TECH: $0.62, $1.46, $0.87, $1.66, $1.76, $1.05, $0.46 TECH ACAD: −$1.60, −$1.79, −$1.05, −$1.34, −$0.37, $1.36, $2.30 ACAD GH: −$0.84, −$2.60, −$4.00, −$6.41, −$4.28, −$3.56, −$3.32 GH PBH: −$0.69, $2.78, $3.25, $4.04, −$1.65, $4.17, $4.29 PBH PGNY: −$0.41, $0.47, $0.66, $0.30, $0.62, $0.57, $0.65 PGNY HAE: $1.04, $1.48, $1.55, $0.84, $2.24, $2.29, $3.31 HAE CAI: -, -, -, -, −$13.24, −$10.66, −$3.22 CAI MDGL: −$5.45, −$13.09, −$14.63, −$17.23, −$19.99, −$21.90, −$12.85 MDGL CORT: $0.77, $0.85, $0.89, $0.87, $0.94, $1.23, $0.82 CORT SHC: −$0.09, −$0.16, $0.41, −$0.83, $0.18, $0.16, $0.27 SHC
SHC is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$21.90 to $4.29. A gap is a year with no number. A ring marks where a line starts: CAI has no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out SHC and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: SHC's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SHC/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.